A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee

NCT01554579 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
171
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)